Northern Michigan University and Micro Imaging Technology to Collaborate on Rapid Detection of Staph and MRSA Pathogens
SAN CLEMENTE, CA--(Marketwired - Oct 25, 2013) - Micro Imaging Technology, Inc. (OTCQB: MMTC) announced today that it will collaborate with the Northern Michigan University (NMU) Department of Biology to expand MIT's technology to identify and differentiate Staphylococcus aureus (S. aureus) and Methicillin Resistant Staphylococcus aureus (MRSA). The goal of the strategic research with NMU is to rapidly and cost-effectively identify these two particular healthcare threats using the MIT 1000 System, a bacterial cell based identification system that can identify pathogenic bacteria in three minutes (average) at significant cost savings per test.
At this stage the collaboration involves scientists from MIT and NMU gathering preliminary data and developing collaborative research proposals seeking funding in support of continued research.
Dr. Josh S. Sharp, Ph.D., assistant professor at the Northern Michigan University Department of Biology, will direct the NMU portion of the research at his laboratory in Marquette, MI. Sharp received a B.S. at Western Michigan University in 1998 and his Ph.D. in Biological Sciences at the Mount Sinai School of Medicine of New York University in 2006. His initial research in this collaboration will focus on clinical applications of the MIT 1000.
"Being able to quickly identify if a patient has an S. aureus infection, and whether or not that S. aureus is MRSA, a strain of S. aureus resistant to certain antibiotics would be extremely useful in dictating the proper course of treatment for that patient, and ultimately increase the likelihood of a successful patient outcome," Sharp said.
Micro Imaging Technology's Chief Scientist, Dr. David Haavig, is the program director of the effort and will lead MIT's team in the collaboration. He received his Ph.D. in Physics from Purdue University in 1983. Haavig was instrumental in developing the MIT 1000, a stand-alone, rapid laser based bacteria detection and identification technology that can detect pathogenic bacteria and complete an identifying test in less than three minutes (average) at significant cost savings per test.
"We are extremely pleased to be working with Dr. Sharp and his staff on this project," Haavig said. "We are confident that this collaborative effort will be highly successful and the result of our teamwork and the clinical implications for this technology may very well prove to be immeasurable."
About: Northern Michigan University
Northern Michigan University, located in Marquette, Michigan, is a dynamic four-year, public, coeducational university that has grown its reputation based on its award-winning leadership programs, cutting-edge technology initiatives and nationally recognized academic programs. The university's fastest growing academic areas are clinical science, biology, and the geographical and environmental sciences. Northern Michigan has a population of about 9,200 undergraduate and graduate students. It offers 180 degree programs, including 18 graduate programs.
About: Micro Imaging Technology, Inc.
Micro Imaging Technology, Inc. is a California-based public company that is also registered to do business under the name Micro Identification Technologies. MIT has developed and patented the MIT 1000, a stand-alone, rapid, optically-based, software driven system that can identify pathogenic bacteria and complete an identification test, after culturing, in three minutes (average) at the lowest cost per test when compared to any other conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process requires only clean filtered water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for more than $3.5 billion, which is expected to surpass $4.7 billion by 2015 according to BCC Research. In addition, the recently passed "New" U.S. Food Safety Bill is expected to further accelerate the current annual growth rate of 6.6 percent.
In June 2009, the AOAC Research Institute (AOAC RI) awarded the Company Performance Tested Methods SM (PTM) certification for the rapid identification of Listeria. The AOAC RI provides an independent third party evaluation and expert reviews of methods and will award PTM certification to methods that demonstrate performance levels equivalent or better than other certified bacteria identifying methods. The MIT System underwent hundreds of individual tests, including ruggedness and accuracy, to earn AOAC RI's certification for the identification of Listeria.
You can find more information about our company and about Micro Identification Technologies(TM) . Please visit our newly enhanced website at www.micro-identification.com.
This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the Securities and Exchange Commission, reference MMTC: www.sec.gov.